Swiss pharma and biotech brands: the 2026 numbers

Roche leads the pharma and biotech ranking

CHF 138.0bn

combined annual revenue of the 15 brands in the ranking

7 of 15

are in the Swiss Lions 100, with 15.8% of its combined revenue

1963

median founding year, excluding brands formed by a merger or spin-off

Pharma and biotech is the second-largest category by revenue, at CHF 138bn, and the most concentrated. Roche and Novartis earn 79% of the total. Roche ranks first in the category and second in the Swiss Lions 100.

Show the data

Score by brand. Pharma and Biotech ranking, Swiss Lions 100, 2026. Red: in the Swiss Lions 100. Source: Swiss Lions 100, 2026 edition.

Category rank	Brand	Overall rank	Score
1	Roche	No. 2	77.3
2	Novartis	No. 5	75.3
3	Lonza	No. 30	56.3
4	Sandoz	No. 52	52.1
5	Ferring	No. 64	49.8
6	Siegfried	No. 80	44.1
7	Galderma	No. 99	40.7
8	CSL Vifor	Outside top 100	40
9	Bachem	Outside top 100	39.3
10	Octapharma	Outside top 100	36.2
11	A.Vogel	Outside top 100	24.8
12	Idorsia	Outside top 100	21
13	Basilea	Outside top 100	19.3
14	PolyPeptide	Outside top 100	18.5
15	Santhera	Outside top 100	12.5

See the full pharma and biotech ranking, with each brand's scores and sources.

Key facts

Largest by revenue

Roche, CHF 63.0bn

Smallest by revenue

Santhera, CHF 77m

Revenue estimates

2 of 15, where the company publishes no figure

Most visible

Novartis, 69.4 out of 100

Average visibility

37.7 (Swiss Lions 100: 52.1)

Oldest

CSL Vifor, 1872

Youngest

Santhera, 2004

Formed by merger, spin-off or renaming

Novartis (merger of Ciba-Geigy and Sandoz) and Idorsia (spin-off from Actelion)

Family or founder control

5 of 15

Owned by a foundation

A.Vogel

Controlled from abroad

CSL Vifor

Swiss made

0 of 15

Validated climate target

9 of 15 (4 net zero)

Most common location

Basel-Stadt and Basel-Landschaft (4 brands each)

Show the data

Revenue and visibility by brand. Pharma and Biotech ranking, Swiss Lions 100, 2026. Source: Swiss Lions 100, 2026 edition.

Brand	Revenue (CHF m)	Estimate	Visibility score
Roche	62,960	no	69.3
Novartis	45,810	no	69.4
Sandoz	7827	no	61.8
Lonza	6870	no	55
Galderma	3976	no	48.4
Octapharma	3,422	no	44.3
Ferring	2350	yes	40.8
CSL Vifor	1,686	no	23.4
Siegfried	1340	no	25.5
Bachem	709	no	34.7
PolyPeptide	366	no	2.6
Basilea	232	no	21.9
Idorsia	221	no	35.1
A.Vogel	115	yes	12.2
Santhera	77	no	21.2

Most of the other brands are known mainly within the industry. They include contract manufacturers such as Lonza, Siegfried and Bachem and younger research companies such as Idorsia. Their average visibility is well below that of the 100 as a whole.